Research Scandal Leads to Resignation of Stanford President
Last year, then Stanford freshman Theo Baker wrote a story for the student paper about how he uncovered data manipulation in research papers where University President Marc Tessier-Lavigne was the lead author. A follow up story looked at key research about the proteins involved in Alzheimer’s that was published in April 2009 while Tessier-Lavigne was an executive at Genentech. A Stanford review found significant flaws in studies over many years. This eventually led to the resignation of Tessier-Lavigne. He will leave the president post at the end of August but will continue to be a tenured professor in biology, according to a New York Times article.
In a recent guest essay in the New York Times, Baker suggests the lab-culture with the focus on winners creates an environment where mistakes and manipulation of data are common. He cites data that about 3.8% of published studies have problematic figures, but only 0.04% of papers are retracted.
Maternal Deaths Expected to Rise Under Abortion Bans
Several recent articles in the media are highlighting the confusion about states’ efforts to limit access to abortion — as well as the medical crises that can happen because of this. KFF Health News highlights Florida’s ban and how one hospital gave a patient antibiotics when she was miscarrying at 16 weeks and then sent her home. She ended up in the hospital for five days as doctors tried to stop her bleeding and save her uterus. ProPublica highlights a patient in Missouri, where doctors determined her fetus was not viable at less than 18 weeks and doctors would not treat her until her condition worsened. She traveled to Illinois for care.
FDA Advisory Committee Votes Down Sotagliflozin in Type 1 Diabetes and CKD
November 1st 2024Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently reviewing the oral therapy as an adjunct to insulin to help control glycemic levels in adults with type 1 diabetes and chronic kidney disease. The agency’s goal date is Dec. 20, 2024.
Read More
ICER Gives Cell Therapy for Post-Transplant Complications High Rating
Published: October 31st 2024 | Updated: October 31st 2024ICER has given tabelecleucel a rating of A, indicating the T cell therapy for Epstein-Barr virus related post-transplant lymphoproliferative disease has a high certainty of substantial net health benefit and would be cost-effective if priced between $143,900 and $273,700.
Read More